Lisinopril Dosing in Renal Impairment
Lisinopril requires dose adjustment when creatinine clearance (CrCl) falls below 30 mL/min, and should be used with caution in patients with severe renal impairment.
Renal Function Thresholds for Lisinopril
Lisinopril is primarily eliminated unchanged through the kidneys, making renal function a critical factor in its dosing. According to the evidence:
- Normal to moderate renal impairment (CrCl ≥30 mL/min): Standard dosing can be used with regular monitoring 1
- Severe renal impairment (CrCl <30 mL/min):
Pharmacokinetic Considerations
The pharmacokinetics of lisinopril are significantly altered in renal impairment:
- Lisinopril is excreted unchanged in the urine 3
- Elimination half-life is relatively unchanged until CrCl falls below 30 mL/min 3
- With CrCl <30 mL/min:
Monitoring Recommendations
When using lisinopril in patients with impaired renal function:
- Measure baseline renal function before initiating therapy
- Monitor serum creatinine and potassium within 1 week of starting treatment or following dose escalation 1
- Temporarily suspend lisinopril during:
- Intercurrent illness
- Planned IV radiocontrast administration
- Bowel preparation prior to colonoscopy
- Major surgery 1
Special Considerations
- Hyperkalemia risk: Patients with renal impairment are at increased risk of developing hyperkalemia when taking lisinopril 5
- Renal function decline: A small initial increase in serum creatinine may occur after starting ACE inhibitors, which typically returns to baseline in most patients 1
- Contraindications:
- Renal artery stenosis 1
- Severe renal failure with rapidly changing renal function
Clinical Approach
- Calculate CrCl using the Cockcroft-Gault formula
- If CrCl ≥30 mL/min:
- Start with standard dosing (typically 10 mg once daily)
- Monitor renal function and electrolytes
- If CrCl <30 mL/min:
- Start with 2.5 mg once daily
- Titrate cautiously if needed
- Do not exceed 5 mg daily
- Monitor renal function and electrolytes more frequently
Despite renal impairment concerns, ACE inhibitors like lisinopril have been shown to reduce microalbuminuria and progression toward end-stage renal dysfunction, making them valuable medications when used appropriately with proper monitoring 1.